Metraipolis › archive › dc_c23b48cccda5
Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in… — Europe PMC PMID:41971281
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41971281
- DOI
- 10.3389/fpubh.2026.1772312
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T19:36:16.635Z
- SHA-256 of the archived text
e0f5fa22b49239c57a8d7e51a9418995dd975e0b5287a389f78e5af5d12ad28a- Stable URL of this page
https://metraipolis.com/documento/dc_c23b48cccda5
How to cite
Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in… — Europe PMC PMID:41971281 — Europe PMC (en), https://europepmc.org/article/MED/41971281 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c23b48cccda5 (Metraipolis archive dc_c23b48cccda5, sha256 e0f5fa22b49239c57a8d7e51a9418995dd975e0b5287a389f78e5af5d12ad28a)
BibTeX
@misc{dcc23b48cccda5,
title = {Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in… — Europe PMC PMID:41971281},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41971281},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c23b48cccda5; sha256 e0f5fa22b49239c57a8d7e51a9418995dd975e0b5287a389f78e5af5d12ad28a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41971281. Agents can read the archived copy with the MCP tool read_document.